PriceSensitive

PolyNovo (ASX:PNV) enters four more European markets

ASX 200
ASX:PNV      MCAP $1.373B
19 November 2020 11:00 (AEST)

PolyNovo (PNV) has entered four more European markets via an extension of its partnership with PolyMedics Innovations (PMI) in Germany.

The company now has access to the markets in Belgium, the Netherlands, Sweden and Luxembourg, in addition to the access granted in Germany, Switzerland and Austria (DACH) in mid-January.

Since then, PMI has already placed four stock orders for PolyNovo’s surgical product, known as NovoSorb BTM.

“Our customers in the DACH region have quickly become believers in NovoSorb BTM and we managed to capture a significant market share this year,” PMI CEO Christian Planck said.

“Therefore, our team is excited about the possibility of bringing NovoSorb BTM to even more customers and patients in these additional four European markets,” he added.

Three patients in Belgium have already been treated with PolyNovo’s NovoSorb BTM product with “excellent” results.

NovoSorb BTM is a synthetic wound dressing that is used to treat severe wounds and burns where the patient has suffered a significant loss of flesh.

“We are very pleased to extend our partnership with PMI. They are an excellent sales organisation with very good relationships with surgeons not only in DACH but also in Sweden, Belgium and the Netherlands,” PolyNovo Managing Director Paul Brennan said.

Despite this, PolyNovo is down 1.36 per cent on the market, with shares trading for $2.90 at 10:31 am AEDT.

Related News